Compare MCI & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCI | LAB |
|---|---|---|
| Founded | 1971 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.6M | 488.4M |
| IPO Year | N/A | 2011 |
| Metric | MCI | LAB |
|---|---|---|
| Price | $20.00 | $1.57 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 40.4K | ★ 1.8M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $169,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.88 | ★ N/A |
| Revenue Growth | N/A | ★ 79.77 |
| 52 Week Low | $12.96 | $0.92 |
| 52 Week High | $19.24 | $2.05 |
| Indicator | MCI | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 57.59 |
| Support Level | $18.65 | $1.54 |
| Resistance Level | $19.45 | $1.66 |
| Average True Range (ATR) | 0.54 | 0.08 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 86.30 | 76.74 |
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.